AyuVis is developing a platform of small molecule immunotherapies that modulate white blood cell activity to combat life-threatening inflammation and infection without causing immunosuppression or contributing to drug resistance. Their approach aims to provide affordable and effective treatments for ICU patients, addressing the limitations of current therapies like steroids and antibiotics.
Funding
Funding not disclosed
Founders
Product
Problem
ICU patients with life-threatening inflammation and infection are often treated with steroids and antibiotics, which can have harmful side effects or contribute to multidrug resistance. Current immunotherapies can be expensive and may not be effective against certain diseases. There is a need for affordable and effective treatments that can modulate the immune system without causing immunosuppression or drug resistance.
Solution
AyuVis is developing a platform of small molecule immunotherapies designed to modulate white blood cell activity, providing a balanced immune response to combat life-threatening inflammation and infection. These immunotherapies aim to prevent tissue and organ damage, promote new cell growth, and circumvent multi-drug resistance. The company's compounds stimulate macrophages to produce a rapid therapeutic response throughout the body. AyuVis's lead candidate has received Orphan Drug and Rare Pediatric Disease designations from the FDA for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants.
Target Audience
The primary target audience includes ICU patients with life-threatening inflammation and infection, particularly preterm infants at risk of bronchopulmonary dysplasia (BPD).
Features
- Novel small molecules that modulate the body's innate immune system
- Compounds designed to activate phagocytosis, reducing the likelihood of multidrug resistance
- Platform technology that restores immune balance while fighting both infection and inflammation
- Lead candidate (AVR-48) with Orphan Drug and Rare Pediatric Disease designations for BPD prevention
- Potential applications in treating acute respiratory distress syndrome (ARDS) and ventilator-associated pneumonia (VAP)
- Simple synthesis and production process for affordable global access